Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data

Autor: van der Ploeg, C. P B, van den Akker-van Marle, M. E., Vernooij-van Langen, A. M M, Elvers, L. H., Gille, J. J P, Verkerk, P. H., Dankert-Roelse, J. E., Loeber, J. G., Triepels, R. H., Van der Ploeg, C. P B, van der Pal, S. M., Dompeling, E., Pals, G., van den Akker van Marle, M. E., Gulmans, V. A M, Oey-Spauwen, M. J W, Wijnands, Y. H H M, Castricum, L. M., Arets, H. G M, van der Ent, C. K., Tiddens, H. A W M, de Rijke, Y. B., Yntema, J. B.
Přispěvatelé: Kindergeneeskunde, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R5 - Optimising Patient Care, Public Health, Human genetics, CCA - Disease profiling
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Pulmonary and Respiratory Medicine
Newborn screening
Pediatrics
medicine.medical_specialty
Cost effectiveness
Genetic counseling
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator
Pancreatitis-Associated Proteins
Research Support
Sensitivity and Specificity
behavioral disciplines and activities
Cystic fibrosis
Decision Support Techniques
Neonatal Screening
SDG 3 - Good Health and Well-being
Antigens
Neoplasm
medicine
Biomarkers
Tumor
Journal Article
Humans
Lectins
C-Type
Comparative Study
Genetic Testing
Pediatrics
Perinatology
and Child Health
Non-U.S. Gov't
Sweat test
Netherlands
medicine.diagnostic_test
business.industry
Public health
Research Support
Non-U.S. Gov't
Infant
Newborn
Cost-effectiveness analysis
Perinatology
Quality-adjusted life year
and Child Health
Pediatrics
Perinatology and Child Health
Mutation
Trypsinogen
Cost-effectiveness
business
Decision analysis
Zdroj: Journal of Cystic Fibrosis, 14(2), 194-202
van der Ploeg, C P B, van den Akker-v Marie, ME, Vernooij-van Langen, A M M, Elvers, L H, Gille, J J P, Verkerk, P H & Dankert-Roelse, J E 2015, ' Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data ', Journal of Cystic Fibrosis, vol. 14, no. 2, pp. 194-202 . https://doi.org/10.1016/j.jcf.2014.08.007
Journal of Cystic Fibrosis, 14(2), 194. Elsevier
Journal of Cystic Fibrosis, 14(2), 194-202. Elsevier Science
Journal of Cystic Fibrosis, 14(2), 194-202. Elsevier
ISSN: 1569-1993
DOI: 10.1016/j.jcf.2014.08.007
Popis: Background: Previous cost-effectiveness studies using data from the literature showed that newborn screening for cystic fibrosis (NBSCF) is a good economic option with positive health effects and longer survival. Methods: We used primary data to compare cost-effectiveness of four screening strategies for NBSCF, i.e. immunoreactive trypsinogen-testing followed by pancreatitis-associated protein-testing (IRT-PAP), IRT-DNA, IRT-DNA sequencing, and IRT-PAP-DNA sequencing, each compared to no-screening. A previously developed decision analysis model for NBSCF was fed with model parameters mainly based on a study evaluating two novel screening strategies among 145,499 newborns in The Netherlands. Results: The four screening strategies had cost-effectiveness ratios varying from sic23,600 to sic29,200 per life-year gained. IRT PAP had the most favourable cost-effectiveness ratio. Additional life-years can be gained by IRT DNA but against higher costs. When treatment costs reduce with 5% due to early diagnosis, screening will lead to financial savings. Conclusion: NBSCF is as an economically justifiable public health initiative. Of the four strategies tested IRT PAP is the most economic and this finding should be included in any decision making model, when considering implementation of newborn screening for CF. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: